Abilify Asimtufii

Approved Indications

Abilify Asimtufii is an atypical antipsychotic medication administered by a healthcare professional as an extended-release injection. It is used for the following purposes in adult patients:

• Schizophrenia: It is used for the ongoing treatment of schizophrenia, a chronic mental health condition that may involve symptoms such as hallucinations, delusions, or disorganized thinking.
• Bipolar I Disorder: It is used as a maintenance treatment for bipolar I disorder. In this role, it is intended to help stabilize mood and prevent or delay the return of manic or mixed episodes.

Usage Considerations

This medication is a long-acting formula designed to be administered once every two months. It is typically prescribed for patients who have already demonstrated that they can tolerate aripiprazole (the active ingredient) in an oral or shorter-acting injectable form. Because it is an extended-release suspension, it provides a steady level of medication in the bloodstream over a long period, which may help with treatment adherence compared to daily oral medications.

Mechanism of Action

The exact way Abilify Asimtufii works in the brain is not fully understood. It is believed to help regulate the activity of neurotransmitters, which are chemical messengers that allow brain cells to communicate. Specifically, it targets dopamine and serotonin, two chemicals that play key roles in mood, thinking, and behavior.

This medication is classified as a partial agonist. This means it can help stabilize brain activity in different ways depending on the environment in the brain:

• Dopamine regulation: It can lower dopamine activity in parts of the brain where it is too high and increase it in areas where it is too low.
• Serotonin regulation: It interacts with serotonin receptors to help balance mood and cognitive functions.

By adjusting these chemical levels, the medication helps reduce symptoms such as hallucinations, delusions, and extreme mood shifts.

Extended-Release Delivery

Abilify Asimtufii is an extended-release injectable suspension. Once the medication is injected into the muscle, it is released slowly into the bloodstream over a long period. This delivery method provides a steady level of the drug in the body for two months, which helps maintain symptom control without the need for daily oral medication.

Common Side Effects

• Injection site reactions, including pain, redness, or swelling
• Restlessness or an urgent need to move (akathisia)
• Weight gain
• Drowsiness or fatigue
• Dizziness
• Constipation
• Nausea

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious side effects:

• Tardive dyskinesia: Uncontrolled or repetitive muscle movements, particularly in the face, tongue, or jaw. This condition may become permanent.
• Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening reaction that causes high fever, stiff muscles, confusion, sweating, and changes in heart rate or blood pressure.
• Metabolic changes: High blood sugar (hyperglycemia), which can lead to diabetes, as well as increases in cholesterol and triglycerides.
• Impulse control problems: New or intense urges to gamble, binge eat, shop, or other impulsive behaviors that are difficult to control.
• Orthostatic hypotension: A sudden drop in blood pressure when standing up, which may cause dizziness or fainting.
• Low white blood cell count: A decrease in white blood cells that can make it harder to fight infections.
• Seizures.
• Difficulty swallowing.

Boxed Warning: Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify Asimtufii is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS)

A potentially fatal condition called Neuroleptic Malignant Syndrome (NMS) has been reported with antipsychotic medications. Symptoms may include high fever, muscle rigidity, confusion, and changes in heart rate or blood pressure. Immediate medical evaluation is necessary if these symptoms occur.

Tardive Dyskinesia

The use of this medication may cause tardive dyskinesia, a syndrome of involuntary and repetitive muscle movements, often in the face or tongue. The risk of developing this condition and the likelihood it will become permanent increase with long-term use.

Metabolic Changes

Atypical antipsychotics are associated with metabolic changes that can increase cardiovascular risk. These include:

• Hyperglycemia and Diabetes: High blood sugar levels, sometimes severe, have been reported. Monitoring for symptoms such as excessive thirst or frequent urination is recommended.
• Dyslipidemia: Changes in cholesterol and triglyceride levels may occur during treatment.
• Weight Gain: Significant weight gain has been observed in patients receiving this medication.

Impulse Control Problems

There have been reports of patients experiencing intense urges, particularly for gambling, and an inability to control those urges while taking aripiprazole. Other reported compulsive behaviors include sexual urges, shopping, and binge eating. These urges may stop if the medication is adjusted or discontinued.

Additional Precautions

• Orthostatic Hypotension: Dizziness or fainting may occur due to a sudden drop in blood pressure when standing up from a sitting or lying position.
• Low White Blood Cell Count: Significant decreases in white blood cell counts have been reported. Patients with a history of low counts may require frequent blood tests during the first few months of therapy.
• Seizures: This medication should be used with caution in individuals with a history of seizures or conditions that lower the seizure threshold.
• Cognitive and Motor Impairment: Somnolence (drowsiness) may occur, which can impair the ability to drive or operate heavy machinery.
• Body Temperature Regulation: Antipsychotics can disrupt the body's ability to reduce its core temperature. Caution is advised during strenuous exercise or exposure to extreme heat.

Pregnancy

There is limited data regarding the use of Abilify Asimtufii in pregnant women to determine a specific risk of birth defects or miscarriage. However, healthcare providers monitor the use of antipsychotic medications like aripiprazole due to known risks during the third trimester.

Infants exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal (movement) and withdrawal symptoms after birth. These symptoms can vary in severity and may include:

• Agitation and tremors
• Increased or decreased muscle tone
• Sleepiness
• Difficulty breathing
• Feeding problems

Some newborns may recover quickly, while others might require specialized medical care or longer hospital stays. Patients are often encouraged to join a pregnancy exposure registry to help healthcare professionals better understand the effects of atypical antipsychotics on pregnancy outcomes.

Breastfeeding

Aripiprazole, the active ingredient in Abilify Asimtufii, is known to pass into human breast milk. There have been reports of poor weight gain in infants who are breastfed while the mother is taking this medication.

Additionally, aripiprazole may interfere with milk production because it can lower prolactin levels in the body. When deciding whether to breastfeed, patients should discuss the potential risks and benefits with their healthcare provider, considering the mother's clinical need for the medication and the health of the infant.

Available Forms

Abilify Asimtufii is supplied as an extended-release injectable suspension.

It comes in pre-filled syringes and is administered by a healthcare provider as an injection into the muscle of the buttocks.

FDA Approval and Indications

Abilify Asimtufii is an extended-release injectable suspension that received FDA approval for administration once every two months. It is indicated for the following uses in adults:

• Treatment of schizophrenia.
• Maintenance monotherapy for bipolar I disorder.

Boxed Warning

The FDA has issued a boxed warning for Abilify Asimtufii because elderly patients with dementia-related psychosis who are treated with antipsychotic drugs face an increased risk of death. This medication is not approved for the treatment of patients with dementia-related psychosis.

Safety Communications

The FDA has warned that aripiprazole, the active ingredient in Abilify Asimtufii, can lead to new or worsening impulse-control problems. These include compulsive gambling, binge eating, excessive shopping, and sexual urges. These urges are reported to be intense and may stop once the medication is discontinued or the dosage is reduced. Healthcare providers are advised to monitor for these behaviors, as patients may not recognize them as being related to the medication.

Regulatory Requirements

Abilify Asimtufii must be dispensed with an FDA-approved Medication Guide. This document provides essential information about the drug's risks, including the potential for serious side effects and the specific warnings associated with its use in certain populations.

Factors Influencing Cost

The total price of Abilify Asimtufii is determined by several factors. Because this medication is a long-acting injection administered by a healthcare professional, the cost often includes both the medication itself and a fee for the medical service or office visit.

• Insurance Coverage: Your out-of-pocket expenses, such as copays or coinsurance, depend on your specific health insurance plan and its formulary.
• Administration Fees: Since you cannot self-administer this drug, you may incur costs related to the clinic or hospital visit where the injection is given.
• Pharmacy Type: This medication is often dispensed through specialty pharmacies, which may have different pricing structures than standard retail pharmacies.

Financial Assistance and Savings

The manufacturer may offer savings cards or patient assistance programs to help reduce the cost for eligible patients. These programs are typically designed for individuals with commercial insurance or those who meet specific financial need criteria. It is recommended to check with the manufacturer or your healthcare provider for current assistance options.

Generic Availability

Abilify Asimtufii is a specialized, long-acting formulation of aripiprazole. While generic versions of oral aripiprazole are widely available and generally less expensive, generic versions of this specific extended-release injection may not be available, which can contribute to a higher cost compared to other forms of the medication.